Recent Updates — SCLX

Scilex Holding Company amended a revolving line of credit with Vivasor, Inc., increasing the maximum aggregate principal amount from $20 million to $30 million. The amendment was executed on September 25, 2026, and approved by the Board of Directors and Audit Committee. No other terms were changed. Dr. Henry Ji serves as CEO of both companies. Scilex Holding Company operates in the healthcare sector, focusing on medical devices and diagnostics.

Scilex Holding Company entered into a binding term sheet with iHolding Group LLP to purchase $100,000,000 of newly issued common stock at an expected price of $15.00 per share, representing approximately 6,666,667 shares. The transaction is subject to customary due diligence, definitive agreements, board approvals, and stockholder approval. Scilex Holding Company is a pharmaceutical company focused on developing and commercializing specialty pain management solutions.

Scilex Holding Company entered into a binding term sheet with Datavault AI Inc. to purchase 837 Bitcoin (BTC) for a total of $50 million. The company plans to pay $30 million initially, with the remaining $20 million in quarterly installments from Q4 2026 through December 31, 2028. Payment can be made in cash, common stock, or subsidiary securities. Scilex Holding Company is a pharmaceutical company focused on developing and commercializing pain management solutions.

Scilex Holding Company held its 2026 Annual Meeting of Stockholders on June 24, 2026. Stockholders representing 100% of Series A Preferred Stock and approximately 63.5% of Common Stock were present. Nominee Dorman Followwill was elected as a Class I director. Shareholders ratified the appointment of BPM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, stockholders approved an amendment to the 2022 Equity Incentive Plan to increase the number of authorized shares to 2,765,789. Scilex Holding Company is a pharmaceutical company.